Phase 1 clinical trial of complement inhibition in primary graft dysfunction after lung transplantation
Active Grant Awarded
- Award ID
- R61HL187358
- Recipient
-
University Of Utah UEI LL8GLEVH6MG3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $397,615
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 12% complete
- Place of performance
- Salt Lake City, UT 84132, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded $397,615 to the University of Utah, Office of Sponsored Projects division, on August 27, 2026, under Assistance Listing 93.837, Cardiovascular Diseases Research, for Grant R61HL187358. The award funds a Phase 1 clinical trial of complement inhibition in primary graft dysfunction after lung transplantation. Primary graft dysfunction is an acute lung injury that occurs within the first 72 hours after transplantation. The principal hypothesis concerns C3 inhibition with pegcetacoplan, a C3 inhibitor FDA-approved for paroxysmal nocturnal hemoglobinuria. The period of performance runs from the August 27, 2026 award date to an ultimate completion date of August 31, 2028. Work is performed in Salt Lake City, Utah 84132. The parent program fosters heart and vascular research across basic, translational, clinical, and population sciences, along with training for young investigators.
Description
- Abstract
- Lung transplantation is the ultimate treatment for individuals with advanced-stage lung disease. However, long- term outcomes after lung transplantation remain disappointing, and the median survival is 6.7 years. Chronic lung allograft dysfunction (CLAD) is the leading cause of death beyond the first year after lung transplantation. Primary graft dysfunction (PGD) is an acute lung injury that occurs in the first 72 hours after lung transplantation and is the leading cause of early morbidity and mortality. Ischemia-reperfusion injury is the primary cause of PGD. Furthermore, PGD is associated with an increased risk of CLAD and impacts long-term survival. Although a number of groups have identified donor and recipient risk factors for PGD, there are no interventions to prevent PGD, and treatment of PGD is limited to supportive care. Emerging clinical and experimental evidence implicates complement activation in the pathogenesis of ischemia-reperfusion injury and PGD after lung transplantation. In addition, there are several complement inhibitors and regulators that are FDA-approved for the treatment of disorders of complement dysregulation. Complement inhibition has been used as a preventative treatment of ischemia-reperfusion injury in kidney transplantation with favorable results. However, there are very limited data regarding the use of complement inhibition in lung transplantation. Pegcetacoplan is an inhibitor of complement component 3 (C3), a central protein in the complement system where the classical, lectin, and alternative pathways converge. By acting proximally at the level of C3, pegcetacoplan provides broad control over complement-mediated inflammation. Pegcetacoplan is FDA-approved for the treatment of paroxysmal nocturnal hemoglobinuria. The principal hypothesis of our proposal is that C3 inhibition with pegcetacoplan initiated before lung transplantation would mitigate the risk of severe PGD. However, because there is limited experience with the use of complement inhibitors, and pegcetacoplan, in lung transplantation, we propose a phase 1 two-center, double-blind, randomized, placebo-controlled trial that aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics of pegcetacoplan in lung transplantation. The study will also assess clinical outcomes, including PGD grades, oxygenation, duration of mechanical ventilation after lung transplantation, and lung function over a 90-day period of follow-up after lung transplantation. These will estimate a treatment effect of pegcetacoplan. The proposed trial will inform the design of a future phase 2 clinical trial that assesses efficacy. Carefully designed and implemented clinical trials are necessary to improve outcomes after lung transplantation.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of California, LOS Angeles | $239,272 |
Quick answers
Who received award R61HL187358?
R61HL187358 was awarded to University Of Utah by National Heart Lung and Blood Institute (National Institutes of Health) on August 27, 2026.
How much is award R61HL187358 worth?
$397,615 has been obligated on R61HL187358.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award